Optimizing CDK4/6 Inhibition in HR+ Breast Cancer

(3:4)

Optimizing adjuvant therapy: chemotherapy necessity in HR-positive breast cancer

(1:19)

Cell cycle inhibitors - CDK4/6 inhibitors

(1:54)

Moving CDK4/6 Inhibition to HER2+ Breast Cancer

(3:25)

Optimizing Adjuvant Treatment of Early Breast Cancer: Where Are We Today?

(27:11)

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

(1:9:24)

Dr. Goetz on Treatment Beyond Progression on CDK4/6 Inhibitors in HR+ Breast Cancer

(2:17)

Investigating mechanisms of resistance to CDK4/6 inhibitors

(50)

Integrating Adjuvant CDK4/6 Therapy for HR+/Her2- EBC | Dr. Naresh Somani | Oncology 2024

(17:47)

Education Session: Trends in Adjuvant Endocrine Therapy

(1:41:26)

The cell cycle - Part 2: Cyclins, cyclin dependent kinases (CDKs), CDK inhibitors

(7:47)

CDK4 6 Inhibitors: Changing the Early Breast Cancer Landscape

(11:42)

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer

(58:22)

Cell cycle regulation, part 5: Cdk Inhibitors

(10:39)

Cell Cycle Regulation | Cell Biology

(23:37)

Cyclins and cdks cell cycle regulation

(16:4)

Metastatic Hormone Positive Breast Cancer | 2023 KU Breast Cancer Year in Review Conference

(26:8)

Considerations for Treating Patients with CDK4/6 Inhibitors

(5:34)

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

(2:6)

HR+ Breast Cancer: Factors in Selecting a CDK4/6 Inhibitor

(4:15)

The Efficacy and Safety of CDK4/6 Inhibitors

(5:50)

What are CDK 4/6 Inhibitors for Breast Cancer?

(7:59)

Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in Breast Cancer

(1:47)

The Efficacy and Safety of CDK4/6 Inhibitors

(6:)

CDK4/6 inhibitors in early stage HR+/HER2- disease

(2:22)

CDK4/6 Inhibitors in the First-line Treatment Setting

(7:40)

Dr Ma on Questions Regarding Treatment Sequencing in CDK4/6 Inhibitor–Resistant Breast Cancer

(2:7)

HR+ Breast Cancer: Risk-Stratifying to CDK4/6 Inhibitors

(3:56)